Vigabatrin in unsatisfactory controlled epilepsies. Swiss Vigabatrin Study Group.
One hundred and twenty-seven patients with uncontrolled epilepsy have been treated in an open add-on study with vigabatrin with a mean follow up of ten months. Mean duration of epilepsy prior to treatment was seven-teen years. Patients with partial seizures, with and without secondary generalisation responded best with 44% achieving a greater than 50% reduction in seizure frequency. Adverse events were primarily CNS related and reversible, two patients were withdrawn because of somnolence and eight because of behavioral disturbances. Reduction of concomittant AEDs was difficult in this population with chronic epilepsy.
Russ
W
W
Institut für Rechtsmedizin, Universität Zürich-Irchel.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000927:Anticonvulsants; D005680:gamma-Aminobutyric Acid; D020888:Vigabatrin